MENU
XBIX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

XBIX stock forecast, quote, news & analysis

The investment seeks daily investment results, before fees and expenses, that correlate to two times (2x) the daily performance of the SPDR S&P Biotech ETF (the "Underlying ETF")... Show more

Category: #Trading
Interact to see
Advertisement
A.I.Advisor
published price charts
XBIX
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for XBIX with price predictions
Oct 30, 2026

XBIX's Stochastic Oscillator remains in overbought zone for 1 day

Expect a price pull-back in the near future.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

XBIX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XBIX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on XBIX as a result. In 1 of 2 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.

Following a +9.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBIX advanced for three days, in 5 of 7 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

A.I.Advisor
published Highlights

Industry description

The investment seeks daily investment results, before fees and expenses, that correlate to two times (2x) the daily performance of the SPDR S&P Biotech ETF (the "Underlying ETF"). Under normal circumstances, the fund will invest at least 80% of the value of its net assets, plus any borrowings for investment purposes, in financial instruments (for example, swaps and futures) that, in the aggregate, provide leveraged exposure to U.S. biotechnology companies equal to approximately two times (200%) the daily performance of such investments. The fund is non-diversified.